Welcome to our dedicated page for Baird Medical Investment Holdings SEC filings (Ticker: BDMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Baird Medical Investment Holdings Ltd. filings document foreign-issuer current reports for a microwave ablation medical device company. The disclosed records include Form 6-K reporting on auditor changes, board and audit committee actions, and financial-reporting controls.
The company's SEC disclosures also address accounting and reporting matters relevant to its Form 20-F status, including U.S. GAAP and SEC reporting requirements, independent registered public accounting firm appointments, and disclosed material weaknesses in internal control over financial reporting.
Baird Medical Investment Holdings Ltd (BDMD) reported strong preliminary, unaudited results for the six months ended June 30, 2026, highlighted by a return to profitability and rapid international expansion. Revenue was $9.9 million, up 24.6% from $8.0 million a year earlier, driven mainly by growth outside the PRC, including the United States and licensing revenue. About two thirds of revenue came from markets outside the PRC, with Hong Kong and the U.S. as key contributors.
Gross profit rose to $8.6 million, with gross margin improving to 87.0% from 82.1%, reflecting a favorable geographic and product mix. Total operating expenses fell sharply to $7.8 million from $17.0 million, mainly due to lower R&D and G&A, partially offset by higher selling and marketing spending to support the U.S. and global commercial ramp. Net income was $13,499, compared with an $11.4 million net loss in the prior-year period. EBITDA improved to $1.6 million and Adjusted EBITDA to $4.0 million, versus EBITDA of $(9.7) million and Adjusted EBITDA of $(3.3) million a year ago.
At June 30, 2026, Baird Medical reported total assets of $73.8 million, total liabilities of $39.2 million and total equity of $34.6 million. Cash and restricted cash were $0.29 million, and accounts receivable were $30.7 million. The company emphasized that U.S. revenue grew to approximately 27% of first-half revenue from less than 2% a year earlier, as it expanded its sales team and geographic coverage.
Baird Medical Investment Holdings Limited is registering up to 11,500,000 Ordinary Shares issuable upon exercise of public warrants at US$11.50 per share and the resale of up to 34,415,562 Ordinary Shares held by various selling securityholders. The company will receive cash only if warrants are exercised; it will not receive any proceeds from selling securityholders’ resales. As of August 5, 2026, the Ordinary Shares closed at US$1.07 and the warrants at US$0.047, making exercise of the warrants unlikely at current prices. The resale shares represent a large portion of the equity and, if sold, could pressure the trading price.
Baird Medical is a Cayman Islands holding company operating in China through wholly owned PRC subsidiaries, focused on microwave ablation systems for thyroid and liver tumors. Revenue was US$31.5 million, US$37.0 million and US$22.5 million in 2023, 2024 and 2025, with net income in 2023–2024 and a US$27.5 million net loss in 2025. The company highlights significant legal and operational risks related to PRC regulation, cash transfer restrictions, and potential trading prohibitions or delisting under the HFCAA, which could materially affect the value of its securities.
Baird Medical Investment Holdings Limited filed Post-effective Amendment No. 2 to its Form F-1, now on Form F-3, updating prior disclosures to reflect an amendment to its 2025 Form 20-F and other information, without registering additional securities or paying new SEC fees.
The registration statement covers the potential primary issuance of up to 11,500,000 Ordinary Shares upon exercise of public warrants with a US$11.50 exercise price, and the resale by selling securityholders of up to 34,415,562 Ordinary Shares acquired at prices well below recent trading levels. As of August 5, 2026, these resale shares represent approximately 63.8% of issued and outstanding Ordinary Shares on a post-exercise basis.
The company reports revenues of US$31.5 million in 2023, US$37.0 million in 2024 and US$22.5 million in 2025, with net income in 2023–2024 and a net loss in 2025. It highlights significant legal and operational risks from its China-based operations, including PRC regulatory oversight, foreign-exchange and cash-transfer constraints, and potential trading prohibitions or delisting risk under the HFCAA if PCAOB inspections of its China-based auditor become restricted.
Baird Medical Investment Holdings Limited, a Cayman Islands holding company with operating subsidiaries in China, filed an amended shelf registration to offer up to US$50,000,000 of ordinary shares, preferred shares, debt securities, warrants and units under Form F-3. Sales are subject to Form F-3 General Instruction I.B.5., limiting primary offerings to no more than one-third of the company’s public float in any 12‑month period while non‑affiliate market value remains below US$75 million.
The company specializes in microwave ablation systems and needles for thyroid and liver tumors, with hospitals in China using its products increasing from approximately 430 in 2022 to 614 in 2025, including Grade III hospitals from 250 to 329. Revenue was US$31.5 million, US$37.0 million and US$22.5 million in 2023, 2024 and 2025, with net income of US$10.7 million and US$12.6 million followed by a US$27.5 million net loss in 2025.
The prospectus highlights extensive China-related regulatory, cash-transfer and HFCAA delisting risks, including PRC controls on dividends and foreign exchange, potential CSRC filing issues for future fund‑raising, and possible U.S. trading prohibitions if PCAOB inspections in China become restricted. No dividends have been paid within the group, and there is no present plan to pay cash dividends. The company is an emerging growth company and foreign private issuer, using reduced U.S. reporting and governance requirements.
ExcelFin SPAC LLC, a ten percent owner of Baird Medical Investment Holdings Ltd, reported its initial holdings of ordinary shares. The disclosure explains that Fin Venture Capital Management, LLC holds 12.5% and Grand Fortune Capital, LLC holds 87.5% of ExcelFin’s membership interests, with related entities GFCHK and GFC also holding ordinary shares. ExcelFin, FVC and GFC disclaim beneficial ownership of the reported shares except to the extent of any pecuniary interest, and actions regarding ExcelFin’s shares require a majority vote of GFCHK’s three-member board of managers.
Baird Medical Investment Holdings Ltd’s ordinary shares are the subject of a Schedule 13D filed by ExcelFin SPAC LLC, Grand Fortune Capital (HK) Company Limited, and Grand Fortune Capital LLC following a business combination involving the issuer.
Based on 36,725,899 ordinary shares outstanding as of January 15, 2026, ExcelFin beneficially owns 4,249,031 shares (11.6%). Grand Fortune Capital LLC beneficially owns 290,000 shares on an as-converted basis from Series A Preferred Shares (0.8%). Grand Fortune Capital (HK) Company Limited is deemed to beneficially own 7,004,016 shares (19.1%), including ExcelFin’s holdings and the convertible preferred position of Grand Fortune Capital LLC. The securities were obtained through the business combination, conversion of working capital loans at $10.20 per share, and a $2.9 million preferred share subscription. The reporting persons state they hold the position for investment purposes and may acquire or dispose of BDMD securities or discuss strategy, governance, and potential transactions with the company.
Baird Medical Investment Holdings Limited, a thyroid-focused microwave ablation device company, reports a sharp reversal in 2025 results. Revenue fell 39.2% to US$22.5 million from US$37.0 million in 2024, and net income of US$12.6 million in 2024 turned into a net loss of US$27.5 million in 2025. Sales remain concentrated in the PRC, though 2025 included contributions from Hong Kong, the United States, Malaysia and Nepal.
The revenue decline stemmed mainly from slower purchasing and more conservative approval procedures at China hospitals amid an anti-corruption campaign, especially affecting direct sales, while distributor revenue rose modestly. Despite lower volume, gross margin stayed high at 83.8%. The loss was driven by a surge in operating expenses to US$44.5 million, including US$17.5 million of share-based compensation and research and development expenses of US$20.1 million tied to FDA and CE work and AI ablation systems.
Liquidity is tight: cash and restricted cash declined to US$0.6 million at December 31, 2025, though working capital was US$22.6 million. Net accounts receivable were US$42.5 million, equal to 188.9% of 2025 revenue, with 777 days of receivable turnover and most balances overdue. About US$5.8 million was collected through May 29, 2026, and management expects substantial additional collections during 2026–2027. The company renewed and added bank facilities at interest rates around 2.70%–2.71% and obtained a US$2.0 million support commitment and non-demand related-party payables. It also secured device registrations in multiple countries and, based on these factors, management concluded there was no substantial doubt about its ability to continue as a going concern for one year from the financial statement issuance date.
Baird Medical Investment Holdings Limited filed a post-effective amendment converting its Form F-1 into a Form F-3 and updated financials and disclosures. The amendment does not register additional securities and enables resale and future issuance under a shelf-style prospectus dated May 22, 2026. The prospectus registers up to 11,500,000 Ordinary Shares issuable upon exercise of warrants at $11.50 per share and up to 34,415,562 Ordinary Shares for resale by selling securityholders. The filing states the company will not receive proceeds from resale by selling securityholders and is unlikely to receive proceeds from warrant exercises at the May 21, 2026 closing price of $1.64 per share. The prospectus highlights China-related regulatory, cash‑transfer and HFCAA/PCAOB inspection risks and summarizes business focus, recent revenues and net income/(loss) for 2023–2025.